MDWD · Underwritten equity offering

MediWound filed a preliminary prospectus supplement for an underwritten public offering of ordinary shares, with size, price and discount to be determined. The filing also discloses preliminary Q3 2026 revenue of approximately $3.6 million, down 33% YoY from $5.4 million, and a cash burn from $53.6M to $28.4M year-to-date. The offering will dilute existing holders and comes amid declining revenue and uncertain U.S. government development services revenue.

• Preliminary Q3 2026 revenue approximately $3.6 million vs $5.4 million in Q3 2025, a 33% decline.
• Cash and equivalents fell to $28.4 million as of September 30, 2026 from $53.6 million at year-end 2025.
• Warrants to purchase 2.13 million shares at $13.475 expire November 27, 2026.
• The offering is a firm-commitment underwritten public offering of ordinary shares; size and price are not yet set.